PainReform Ltd.

PRFX

IL0011651580

PAINREFORM LTD is a Israel-based pharmaceutical Company. The Companyâs main activity is to develop reformulation of established pain therapeutics. PainReform Ltd provides technology, which is dedicated to prolong and enhance efficacy, minimize adverse effects and increase patients convenience as well as faster return of motor function.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.8101 USD

Average target price

11 USD

Spread / Average Target

+1,257.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PAINREFORM LTD.	-70.54%	2M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.8101 ^USD	-3.47%		-7.73%	-70.54%

Apr. 16	PainReform Prices $4 Million Offering; Shares Tumble Pre-Bell	MT
Apr. 09	Painreform Ltd. Announces Groundbreaking Results from New Studies Demonstrating the Superior In-Vitro Release Rates of PRF-110	CI

PainReform Prices $4 Million Offering; Shares Tumble Pre-Bell	Apr. 16	MT
Painreform Ltd. Announces Groundbreaking Results from New Studies Demonstrating the Superior In-Vitro Release Rates of PRF-110	Apr. 09	CI
PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy	Apr. 02	CI
PainReform Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief	Jan. 03	CI
PainReform Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 15	CI
PainReform Ltd. Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File	23-09-11	CI
PainReform Ltd. Announces Selection for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary	23-09-07	CI
PainReform Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-10	CI
Top Premarket Gainers	23-07-20	MT
PainReform Regains Compliance With Nasdaq Listing Rule	23-07-19	MT
Sector Update: Health Care Stocks Advancing Late Friday	23-07-14	MT
Sector Update: Health Care	23-07-14	MT
PainReform Prices $1.5 Million Securities Offering; Shares Surge	23-07-14	MT
Top Premarket Gainers	23-07-14	MT
Sector Update: Health Care Stocks Slipping Late Wednesday	23-07-12	MT
Top Midday Decliners	23-07-12	MT
PainReform Plans to Raise $2.7 Million in Gross Proceeds in Registered Direct Offering, Private Placement; Shares Plunge	23-07-12	MT
Top Premarket Decliners	23-07-12	MT
Top Premarket Decliners	23-07-07	MT
PainReform's Second Part of Phase 3 Trial of PRF-110 Faces Potential Delay	23-06-07	MT
PainReform Ltd. Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery	23-06-07	CI
PainReform Ltd. Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery	23-05-18	CI
PainReform Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
PainReform Ltd. Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery	23-05-01	CI

PainReform Ltd.

Equities